Rockwell Medical Announces Product Purchase Agreement with Leading At-Home and Acute Care Dialysis Provider
09 9월 2024 - 7:00PM
Business Wire
Provides Customer with the only hemodialysis
concentrates convenience pack in the dialysis marketplace to
support its at-home and acute care patient populations
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a
healthcare company that develops, manufactures, commercializes, and
distributes a portfolio of hemodialysis products to dialysis
providers worldwide, today announced a product purchase agreement
with the leading at-home and acute care dialysis provider in the
United States (the "Customer"). Under the terms of the agreement,
Rockwell Medical will supply the Customer with the Company's liquid
acid RenalPure® and liquid bicarbonate SteriLyte®, both of which
will be packaged in either the Company's four-per-case packaging
for larger dialysis settings or two-per-case packaging for smaller
acute care and at-home care settings.
"This customer has a leading patient-centric care model that
addresses the increasing demand for technological advancements in
the dialysis space," said Tim Chole, Chief Commercial Officer at
Rockwell Medical. "The underserved at-home hemodialysis segment
presents an exciting evolution, offering patients an alternative to
traveling, in many instances, several hours, multiple times a week
to receive their life-sustaining hemodialysis treatments. We are
pleased to be this Customer's preferred provider domestically and
internationally for liquid acid and liquid bicarbonate hemodialysis
concentrates products. Additionally, we are proud to support this
Customer's vision to transform the dialysis experience for patients
and make dialysis available anytime, anywhere."
Rockwell Medical's convenience pack includes two 1-gallon
pre-mixed containers of one of the Company's hemodialysis
concentrates products, RenalPure or SteriLyte, offering a number of
advantages for home patients, caregivers, healthcare providers, and
acute facilities including easier handling and streamlined
workflow. For more information, visit
www.rockwellmed.com/hemodialysis-products.
About Rockwell Medical
Rockwell Medical, Inc. (Nasdaq: RMTI) is a healthcare company
that develops, manufactures, commercializes, and distributes a
portfolio of hemodialysis products for dialysis providers
worldwide. Rockwell Medical's mission is to provide dialysis
clinics and the patients they serve with the highest quality
products supported by the best customer service in the industry.
Rockwell is focused on innovative, long-term growth strategies that
enhance its products, its processes, and its people, enabling the
Company to deliver exceptional value to the healthcare system and
provide a positive impact on the lives of hemodialysis patients.
Hemodialysis is the most common form of end-stage kidney disease
treatment and is typically performed at freestanding outpatient
dialysis centers, hospital-based outpatient centers, skilled
nursing facilities, or in a patient’s home. Rockwell Medical's
products are vital to vulnerable patients with end-stage kidney
disease, and the Company is relentless in providing unmatched
reliability and customer service. Rockwell Medical is the second
largest supplier of acid and bicarbonate concentrates for dialysis
patients in the United States and has the vision of becoming the
leading global supplier of hemodialysis concentrates. Certified as
a Great Place to Work® in 2023 and 2024, Rockwell Medical is Driven
to Deliver Life-Sustaining Dialysis SolutionsTM. For more
information, visit www.rockwellmed.com.
Forward-Looking Statements
Certain statements in this press release may constitute
"forward-looking statements" within the meaning of the federal
securities laws. Words such as, "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue," "could,"
"can," "would," "develop," "plan," "potential," "predict,"
"forecast," "project," "intend," "look forward to," "remain
confident," “are determined,” “are on track,” “are resolute in our
vision,” or the negative of these terms, and similar expressions,
or statements regarding intent, belief, or current expectations,
are forward looking statements. There can be no assurance that
Rockwell Medical will become the leading global supplier of
hemodialysis concentrates. While Rockwell Medical believes these
forward-looking statements are reasonable, undue reliance should
not be placed on any such forward-looking statements, which are
based on information available to us on the date of this release.
These forward-looking statements are based upon current estimates
and assumptions and are subject to various risks and uncertainties
(including, without limitation, those set forth in Rockwell
Medical's SEC filings), many of which are beyond our control and
subject to change. Actual results could be materially different.
Risks and uncertainties include, but are not limited to those risks
more fully discussed in the "Risk Factors" section of our Annual
Report on Form 10-K for the year ended December 31, 2023, as such
description may be amended or updated in any future reports we file
with the SEC. Rockwell Medical expressly disclaims any obligation
to update our forward-looking statements, except as may be required
by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240909835914/en/
Heather R. Hunter SVP, Chief Corporate Affairs Officer (248)
432-1362 IR@RockwellMed.com
Rockwell Medical (NASDAQ:RMTI)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024
Rockwell Medical (NASDAQ:RMTI)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024